Skip to content
Open access

A Ferrous-Supply-Regenerating Lipid Nanoparticle Integrating RNAi Induces Ferroptosis for Cancer Therapy.

Jul 2026 · Small · pp. e74925 · 0 citations · 70 references
Medicine

TL;DR

This study is the first to integrate a ferrous-supply-regeneration system with siRNA into a single LNP platform, offering a selective ferroptosis-inducing strategy for ocular cancers and other ferroptosis-sensitive malignancies.

Abstract

Targeting iron-dependent ferroptosis with siRNA has emerged as a promising strategy for cancer treatment. The concept of ferrous-supply regeneration, inspired by electro-Fenton technology, has also gained interest as a non-apoptotic approach to induce ferroptosis. However, integrating both strategies into a single lipid nanoparticle (LNP) remains challenging. To address this, we developed ALSF, a novel LNP in which DSPC is replaced with arachidonic acid (AA) to enable co-delivery of Glutathione Peroxidase 4-siRNA (GPX4-siRNA) and Fe3 +. ALSF facilitates acid- and H2O2-dependent iron recycling, continuously regenerating Fe2 + to drive ROS production, while GPX4-siRNA silences GPX4 to induce lipid peroxidation (LPO) and ferroptosis. Elevated H2O2 levels in cancer cells promote selective iron recycling, lysosomal disruption, and siRNA escape, enabling effective gene knockdown at lower doses. In vivo, ALSF suppressed tumor growth in a C918 xenograft model with favorable biosafety. This study is the first to integrate a ferrous-supply-regeneration system with siRNA into a single LNP platform, offering a selective ferroptosis-inducing strategy for ocular cancers and other ferroptosis-sensitive malignancies.

Read PDF

Similar papers

Sep 2026

Autophagy-mediated amplification of ferroptosis via a curcumin-loaded metal-enzyme nanoplatform for synergistic tumor therapy.

Ferroptosis is an iron-mediated cell death process driven by lipid peroxidation, yet its antitumor potential is often counteracted by the limited endogenous H2O2 content, the strict catalytic conditions required for the Fenton reaction, and protective autophagy. Notably, sustained autophagy drives ferritin degradation...

Chen-Shuo Wang, Zhen-Zhen Ma, Meng-Yu Liu et al. · 0 citations
Review Open access Sep 2026

Ferroptosis nanomedicine for cancer therapy: strategies and challenges

The biological rationale for ferroptosis-targeted cancer therapy is summarized, major translational barriers are analyzed, and nanomedicine strategies that may move ferroptosis induction from experimental proof of concept toward clinically interpretable intervention are synthesized.

Yan-Pin Ma, Zi-Yi Xu, Huda Akram et al. · 0 citations
Sep 2026

A mitochondria-targeted supramolecular nanoplatform overcomes cisplatin resistance via self-amplified ferroptosis.

An upregulated GPX4 level of tumor cells with enhanced antioxidant defense systems accounts substantially for cisplatin resistance, but on the other hand, offers a unique therapeutic strategy due to the improved sensitivity of tumor cells to ferroptosis. Effective ferroptosis induction remains a challenge owing to insu...

Ying Liu, Zong-Tao Zhou, Wei Ma et al. · 0 citations
Sep 2026

Glutathione-Driven Redox Inducer with Disruption of the SLC7A11/GSH/GPX4 Axis for Enhanced Ferroptotic Therapy

A glutathione-responsive metal–organic framework nanoplatform for the co-delivery of curcumin and a GPX4-targeting antisense oligonucleotide (ASO) demonstrated robust anticancer effects in 3D multicellular tumor spheroids with a promoted oxidative imbalance.

Sen Li, Wen-Tao Wang, Yi-Zhang Chen et al. · 0 citations
Sep 2026

Sorafenib-Loaded Copper Phosphate Nanoparticles with Redox Balance Disruption and Autophagy Blockage Capacities for Enhanced Tumor Ferroptosis and Cuproptosis

In vitro and in vivo data demonstrated that these CuPi-SRF-PAA NPs could achieve effective tumor suppression with high biocompatibility and highlights the key roles of combining redox balance disruption and autophagy blockage in tumor therapy.

Y. Ouyang, Ya-Qin Hu, Chun-Mei Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.